| 7 | | Please join ZOOM meeting at: **https://cern.zoom.us/j/96325392842?pwd=cnNGeWhGeHlsb09PY0tVTEYwWUdlUT09** |
| | 7 | == Summary of actions == |
| | 8 | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| | 9 | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| | 10 | * **KL/KK**: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| | 11 | * **KL**: Ensure one representative per group at the next LhARA SG meeting. |
| | 12 | * **KL**: Raise NIHR engagement with K.Gleeson. |
| | 13 | * **KL**: Seek PPI representative for SG. |
| | 14 | * **KK, JPar, CW, KL**: Make relevant contact with local PPI groups as described in item 4. |
| | 15 | * **KL&JPar**: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites. |
| | 16 | * **KK, JPar, CW, KL, SG**: Make relevant contact with local clinician groups as described in item 4. |
| | 17 | * **KL**: Review proposed w/p structure and skills matrix taking into account comments under item 4. |
| | 18 | * **KL/RMcL**: Liaise to generate small group to coordinate development of instrumentation aspects of the programme. |
| | 19 | |
| | 20 | == Notes == |
| | 21 | |
| | 22 | 1. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:] |
| | 23 | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| | 24 | * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. |
| | 25 | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| | 26 | * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. Agreed, morph action to include all. |
| | 27 | * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| | 28 | * **Stands.** Agenda item. |
| | 29 | * **KL** Send out diary invitation straight away to get it into the diary. |
| | 30 | * **Done.** |
| | 31 | |
| | 32 | 2. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\ |
| | 33 | See slides which contain a brief status report as well as the provocation of the discussion for agenda item 4. |
| | 34 | |
| | 35 | 3. Discussion of SG composition: KL/All |
| | 36 | - We agreed to re-set the SG composition to include one representative per group, the work-package managers (once they are defined), and co-opted members as required. **KL** will work towards proper representation at the next SG meeting. |
| | 37 | - JPar noted that it would be important to make sure that groups were represented in the meeting and insitute Directors may need to be encouraged to delegate appropriately. |
| | 38 | |
| | 39 | 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All |
| | 40 | * Dealing with feedback from our 2019 submission: \\ |
| | 41 | "//Engagement with patients, clinicians and industry could have been strengthened//" |
| | 42 | - Patient engagement: |
| | 43 | - Actions taken to date include engagement with the PPI group at CXH in London. These contacts will be taken forward. |
| | 44 | - We **agreed**: |
| | 45 | - Make local contacts by partner: |
| | 46 | - **KK**: Manchester |
| | 47 | - **JPar**: Liverpool |
| | 48 | - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD |
| | 49 | - **KL**: Will contact K.Prise in Belfast to see whether/how contact to PPI can be made. |
| | 50 | - With local contacts made we'll try and coordinate broader activity, Perhaps K.Gleeson (CXH) may take a role here. |
| | 51 | - CTRAD: important to bring Workstreams 1 and 4 into the patient- and clinician-engagement activities. **KL&JPar** will write to KK in her capacity as W/s4 chair to ask for help in this regard. |
| | 52 | - NIHR: Various local groups, including one in London with which K.Gleeson is in contact. Seek to exploit NIHR. **KL** will raise possibility with K.Gleeson. |
| | 53 | - General comment from SG: need to ask what is important to patients. We discussed co-opting a PPI member to our SG. **KL** agreed to ask the author of the Lay Summaries of the pre-CDR and the publication if he would be willing to play this role. |
| | 54 | - Clinician engagement: |
| | 55 | - Within Imperial Trust and College contacts with clinicians and medical physicists good and being strengthened. We discussed the need to develop links with clinicians at the various partner institutes. We **agreed**: |
| | 56 | - **SG**: Birmingham |
| | 57 | - **JPar**: Liverpool |
| | 58 | - **KK**: Manchester (perhaps in collaboration with N. Burnett) |
| | 59 | - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD |
| | 60 | - **KL**: Contact K. Prise and M. Borghesi re clinician contact in Belfast. |
| | 61 | - As in the case of patient engagement we **agreed** to contact CTRAD to seek support in reaching out. **KL/JPar** will write to the KK to seek support in this endeavour. |
| | 62 | - Industrial engagement: |
| | 63 | - Some contacts made at time of preparation of last meeting and need to push forward to enhance the industrial engagement going forward. After discussing how to proceed we **agreed**: |
| | 64 | - **KL**: Will write to J.Clarke to ask for support to reach out to relevant industry. |
| | 65 | - **PA**: Will make contact with MTC to see how to make contact with relevant industry. **PA/KL** will cooperate in drafting a letter. |
| | 66 | - Possible engagement: Teledyne-E2V; Oxford Instruments, FMD-Oxford, STFC engagement team. |
| | 67 | - We noted the possibility that we should get a person to coordinate our industrial engagement. |
| | 68 | * Slides to initiate discussion of (done under 2 above): |
| | 69 | - Scope: we agreed to target first radiobiology exposures on LhARA within the 5-year scope of the bid. |
| | 70 | - We discussed the w/p structure. KK pointed out that it needed to map explicitly to the EPSRC priority deliverables. **KL** will take a second look at the proposed w/p structure and propose a revision. |
| | 71 | - Stakeholders from whom we should be seeking support; --All-- |
| | 72 | - TKW proposed to make a diagram showing expertise required vs expertise available. **KL** will coordinate the creation of such a diagram. This diagram will also be valuable in negotiations with partners. |
| | 73 | |
| | 74 | 5. Follow-up discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all |
| | 75 | - KL reported that R.McLauchlan (CXH) had agreed to take an overview/coordinating role in this area. RMcL explained the vision to bring people together to understand what the opportunities are and how to bring the activity together into a coherent programme. |
| | 76 | - PA pointed out the need to take a staged approach with an initial focus on making sure the beam delivered is appropriate. |
| | 77 | - JPar pointed out that Liverpool has a Centre for Pre-Clinical Imaging. |
| | 78 | - We agreed to work towards a small sub-group to guide the development of the meeting and subsequently guide the development of the activity. **KL/RMcL** will liaise to bring this about. |
| | 79 | |
| | 80 | 6. DONMs \\ |
| | 81 | * 04 Sep 2020; 10:00 BST |
| | 82 | |
| | 83 | 7. AoB \\ |
| | 84 | - None. |
| | 85 | |
| | 86 | ---- |
